Emerging data suggests that Cilgavimab, formerly known as COV2-2130, holds significant capability as a medicinal agent in combating COVID-19. This immunoglobulin exhibits a novel mechanism of action , specifically targeting the pathogen's ACE2-RBD with exceptional binding power. Early studies show a robust ability to inhibit viral entry , possibly